Shrikant Tamhane1,2,3, Rene Rodriguez-Gutierrez3,4, Anoop Mohamed Iqbal5, Larry J Prokop1, Irina Bancos2, Phyllis W Speiser6, Mohammad Hassan Murad1. 1. Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota. 2. Division of Endocrinology, Mayo Clinic, Rochester, Minnesota. 3. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota. 4. Division of Endocrinology, Hospital Universitario "Dr. José E. Gonzalez," Universidad Autonoma de Nuevo León, Monterrey, México. 5. Department of Pediatric Endocrinology, Division of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota. 6. Division of Pediatric Endocrinology, Cohen Children's Medical Center and Zucker Hofstra Northwell School of Medicine, Lake Success, New York.
Abstract
Background: Individuals with congenital adrenal hyperplasia (CAH) require glucocorticoid therapy to replace cortisol and to control androgen excess. We sought to evaluate the effects of glucocorticoid therapy on cardiovascular and metabolic outcomes in individuals with CAH. Methods: We searched bibliographical databases through January 2016 for studies evaluating cardiovascular risk factors in individuals with CAH treated with glucocorticoids compared with controls without CAH. We used a random-effects model to synthesize quantitative data. Results: We included 20 observational studies (14 longitudinal, six cross-sectional) with a moderate to high risk of bias. The average dose of glucocorticoids (in hydrocortisone equivalents) was 9 to 26.5 mg/m2/d. In the meta-analysis (416 patients), compared with controls without CAH, individuals with CAH had increased systolic blood pressure [weighted mean difference (WMD), 4.44 mm Hg; 95% CI, 3.26 to 5.63 mm Hg], diastolic blood pressure (WMD, 2.35 mm Hg; 95% CI, 0.49 to 4.20 mm Hg), homeostatic model assessment of insulin resistance (WMD, 0.49; 95% CI, 0.02 to 0.96), and carotid intima thickness (WMD, 0.08 mm; 95% CI, 0.01 to 0.15 mm). No statistically significant differences were noted in fasting blood glucose, insulin level, glucose, or insulin level after 2-hour glucose load or serum lipids. Data on cardiac events were sparse, and most of the literature focused on surrogate outcomes. Conclusion: Individuals with CAH demonstrate a high prevalence of cardiovascular and metabolic risk factors. The current evidence relies on surrogate outcomes. Long-term prospective studies are warranted to assess strategies for reducing cardiovascular risk in individuals with CAH.
Background: Individuals with congenital adrenal hyperplasia (CAH) require glucocorticoid therapy to replace cortisol and to control androgen excess. We sought to evaluate the effects of glucocorticoid therapy on cardiovascular and metabolic outcomes in individuals with CAH. Methods: We searched bibliographical databases through January 2016 for studies evaluating cardiovascular risk factors in individuals with CAH treated with glucocorticoids compared with controls without CAH. We used a random-effects model to synthesize quantitative data. Results: We included 20 observational studies (14 longitudinal, six cross-sectional) with a moderate to high risk of bias. The average dose of glucocorticoids (in hydrocortisone equivalents) was 9 to 26.5 mg/m2/d. In the meta-analysis (416 patients), compared with controls without CAH, individuals with CAH had increased systolic blood pressure [weighted mean difference (WMD), 4.44 mm Hg; 95% CI, 3.26 to 5.63 mm Hg], diastolic blood pressure (WMD, 2.35 mm Hg; 95% CI, 0.49 to 4.20 mm Hg), homeostatic model assessment of insulin resistance (WMD, 0.49; 95% CI, 0.02 to 0.96), and carotid intima thickness (WMD, 0.08 mm; 95% CI, 0.01 to 0.15 mm). No statistically significant differences were noted in fasting blood glucose, insulin level, glucose, or insulin level after 2-hour glucose load or serum lipids. Data on cardiac events were sparse, and most of the literature focused on surrogate outcomes. Conclusion: Individuals with CAH demonstrate a high prevalence of cardiovascular and metabolic risk factors. The current evidence relies on surrogate outcomes. Long-term prospective studies are warranted to assess strategies for reducing cardiovascular risk in individuals with CAH.
Authors: Dong Ho Lee; Sung Hye Kong; Han Na Jang; Chang Ho Ahn; Seung Gyun Lim; Young Ah Lee; Sang Wan Kim; Jung Hee Kim Journal: Arch Osteoporos Date: 2022-03-08 Impact factor: 2.617
Authors: Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White Journal: Endocr Rev Date: 2022-01-12 Impact factor: 19.871
Authors: Margaret Banker; Muraly Puttabyatappa; Patrick O'Day; Jaclyn M Goodrich; Angela S Kelley; Steven E Domino; Yolanda R Smith; Dana C Dolinoy; Peter X K Song; Richard J Auchus; Vasantha Padmanabhan Journal: J Clin Endocrinol Metab Date: 2021-03-08 Impact factor: 5.958
Authors: Deborah P Merke; Ashwini Mallappa; Wiebke Arlt; Aude Brac de la Perriere; Angelica Lindén Hirschberg; Anders Juul; John Newell-Price; Colin G Perry; Alessandro Prete; D Aled Rees; Nicole Reisch; Nike Stikkelbroeck; Philippe Touraine; Kerry Maltby; F Peter Treasure; John Porter; Richard J Ross Journal: J Clin Endocrinol Metab Date: 2021-04-23 Impact factor: 5.958